Quan điểm mới về các tác nhân kháng khuẩn: Điều trị COVID-19 bằng Remdesivir

Antimicrobial Agents and Chemotherapy - Tập 65 Số 1 - 2020
Muneerah M Aleissa1, Emily Silverman2, Luisa M. Paredes Acosta3,4, Cameron T. Nutt3,4, Aaron Richterman5, Francisco M. Marty3,2,4
1Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA
2Division of Infectious Diseases, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA
3Department of Medicine, Brigham and Women's Hospital Boston, Massachusetts USA
4Harvard Medical School Boston Massachusetts USA
5Division of Infectious Diseases, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

Tóm tắt

Remdesivir gần đây đã được Cục Quản lý Thực phẩm và Dược phẩm Hoa Kỳ phê duyệt để điều trị cho các bệnh nhân nhập viện với bệnh do virus corona 2019 (COVID-19). Remdesivir là tiền chất của một chất tương tự adenosine có khả năng ức chế sự nhân lên của nhiều họ virus RNA, bao gồm Coronaviridae . Dữ liệu tiền lâm sàng từ các mô hình động vật của các bệnh do virus corona, bao gồm COVID-19, đã chứng minh rằng việc điều trị sớm bằng remdesivir có thể cải thiện tỉ lệ sống sót, giảm tổn thương phổi và giảm mức độ RNA của virus.

Từ khóa

#Remdesivir; COVID-19; điều trị; virus corona; RNA; tiền lâm sàng; ức chế

Tài liệu tham khảo

10.3390/ijms21072657

10.7150/ijbs.45053

10.1038/s41586-020-2012-7

10.3390/jcm9041225

10.7326/m20-5008

10.1007/s11845-020-02218-2

World Health Organization. 2020. WHO coronavirus Disease (COVID-19) dashboard. https://covid19.who.int/. Accessed 29 October 2020.

U.S. Food and Drug Administration. 1 May 2020. Coronavirus (COVID-19) update: FDA issues Emergency Use Authorization for potential COVID-19 treatment. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. Accessed 26 June 2020.

European Medicines Agency. 25 June 2020. First COVID-19 treatment recommended for EU authorization. https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation. Accessed 20 August 2020.

Gilead. 3 July 2020. European Commission grants conditional marketing authorization for Gilead’s Veklury (remdesivir) for the treatment of COVID-19. https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/european-commission-grants-conditional-marketing-authorization-for-gileads-veklury-remdesivir-for-the-treatment-of-covid19#:~:text=In%20recognition%20of%20the%20current Emirates%20and%20the%20European%20Union. Accessed 20 August 2020.

U.S. Food and Drug Administration. 2020. Veklury (remdesivir) EUA letter of approval. Reissued 22 October 2020. https://www.fda.gov/media/137564/download. Accessed 22 October 2020.

10.1021/acscentsci.0c00489

10.1136/bmj.m1610

10.1371/journal.ppat.1006889

10.1534/genetics.113.154963

10.1038/nm.2972

10.1371/journal.ppat.1003565

10.1128/mBio.00221-18

10.1074/jbc.RA120.013679

10.1038/srep43395

10.1038/nature17180

10.1126/scitranslmed.aal3653

10.1038/s41422-020-0282-0

10.1093/cid/ciaa1474

10.1038/s41467-019-13940-6

10.1073/pnas.1922083117

10.1038/s41586-020-2423-5

European Medicines Agency. 2020. Summary on compassionate use—remdesicir Gilead. https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf. Accessed 13 June 2020.

10.1021/acsmedchemlett.0c00316

10.1111/cts.12840

World Health Organization. 2018. Deliberations on design options for randomized controlled clinical trials to assess the safety and efficacy of investigational therapeutics for the treatment of patients with Ebola virus disease. https://www.who.int/ebola/drc-2018/summaries-of-evidence-experimental-therapeutics.pdf?ua=1. Accessed 15 June 2020.

10.1186/s13054-015-0753-8

U.S. Food and Drug Administration. July 2020. Fact sheet for health care providers Emergency Use Authorization (EUA) of Veklury (remdesivir). https://www.fda.gov/media/137566/download. Accessed 28 October 2020.

NIH. 2020. COVID-19 treatment guidelines. https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/remdesivir/. Accessed 21 September 2020.

10.1093/infdis/jiaa446

10.1016/S0140-6736(20)31022-9

World Health Organization. 18 February 2020. COVID-19 therapeutic trial synopsis. https://www.who.int/publications-detail/covid-19-therapeutic-trial-synopsis. Accessed 13 June 2020.

10.1056/NEJMoa2007764

10.1056/NEJMoa2015301

10.1001/jama.2020.16349

Pan H Peto R Karim QA Alejandria M Henao-Restrepo AM Hernández García C Kieny MP Malekzadeh R Murthy S Preziosi MP Reddy S Roses Periago M Sathiyamoorthy V Røttingen JA Swaminathan S. 2020. Repurposed antiviral drugs for COVID-19–interim WHO SOLIDARITY trial results. medRxiv Preprint doi:10.1101/2020.10.15.20209817.

World Health Organization. 2020. An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care. https://www.who.int/publications/m/item/an-international-randomised-trial-of-additional-treatments-for-covid-19-in-hospitalised-patients-who-are-all-receiving-the-local-standard-of-care. Accessed 21 October 2020.

Cochrane Methods. 2020. RoB 2: a revised Cochrane risk-of-bias tool for randomized trials. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials. Accessed 21 October 2020.

World Health Organization. 2020. Global COVID-19 clinical platform: rapid core case report form (CRF). https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical_CRF-2020.4. Accessed 21 October 2020.

10.1016/j.ajog.2020.08.001

10.1093/cid/ciaa1466

10.1056/NEJMoa1910993

10.1093/infdis/jiw493

10.1093/jpids/piaa045

10.1681/ASN.2020050589

10.1002/jps.22109

10.1128/AAC.01540-09

10.1128/AAC.01521-20

10.1016/j.ekir.2020.10.005

10.1093/cid/ciaa1637

10.1093/infdis/jiaa666

10.1136/bmj.g2547

10.1056/NEJMoa2021436

10.1016/S2213-2600(19)30253-X

10.1177/1740774517697919